Tags Archive Navigation
icon
-
Media ReleaseNovartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
-
Media ReleaseNew data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
-
Media ReleaseNovartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
-
Media ReleaseNovartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
-
Media ReleaseNovartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
-
Media ReleaseNovartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
-
Media ReleaseNovartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer
-
Media ReleaseNovartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
-
Media ReleaseNovartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year**
-
Media ReleaseNovartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema
-
Media ReleaseNovartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
-
Media ReleaseNovartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G
Pagination
- ‹ Previous page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- …
- 29
- › Next page